David Blech

Last updated

David Abraham Blech (born November 25, 1955) is an American businessman, investor, and venture capitalist. He is one of the financial pioneers of the biotech industry and was once known as the "King of Biotech".

Contents

Early life and education

Blech grew up in Brooklyn, New York. [1] Blech graduated from Baruch College and earned a Master's in Music Education at the Teacher's College of Columbia University. [2]

Early career

Since 1980, Mr. Blech has been a founder of companies and venture capital investor in the biotechnology sector. His initial venture investment, Genetic Systems Corporation, which he helped found with his father and his brother Isaac Blech, was built around promising scientists, including the high profile microbiologist Robert Nowinski. It developed the first inexpensive and accurate test to diagnosis sexually-transmitted diseases using monoclonal antibodies, allowing tens of thousands of babies to be born to women who otherwise would have become sterile from pelvic inflammatory disease. [3] The company was sold to Bristol Myers in 1986 for $294 million (3%) of Bristol Myers stock. [4]

In 1989, Blech co-founded Icos Corporation with Nowinski and George B. Rathmann, receiving the largest start up financing in biotech history at $33 million. Icos discovered the drug Cialis, which was acquired by Eli Lilly in 2003 for over $2.6 billion. The Blechs also co-founded Celgene Corporation in 1986, which was a unit of the Celanese Corporation, and was spun off as an independent company following the merger of Celanese Corporation with American Hoechst Corporation. Celgene introduced two major cancer drugs, and has a current value of over $35 billion, making it the 5th largest biotech company in the world. [5]

Other companies he helped found include DNA Plant Technology, Neurogen Corporation, Incyte Pharmaceuticals, Alexion Pharmaceuticals, ARIAD Pharmaceuticals, Neurocrine Biosciences, Cytosorbents Inc, and Intellect Neurosciences. He was also instrumental in the turnaround of Liposome Technology Inc. and Biotech General Corporation. In 1990, Mr. Blech founded D. Blech & Company, which, until it ceased doing business in September 1994, was a registered broker-dealer involved in underwriting biotechnology issues.[ citation needed ] At his peak in 1992, Blech's wealth was estimated at almost $300 million, briefly making him a member of the Forbes 400. [6]

Falling deep into debt, D. Blech & Co was in violation of net capital rules and ceased operations on September 22, 1994, a day that came to be known as "Blech Thursday" in the biotech industry. [5]

Blech came under investigation by the SEC for securities fraud. During the investigation Lloyd Schwed, a Florida-based attorney representing a group of former brokers, attempted to blackmail Blech by promising to withhold tapes subpoenaed during the investigation. Blech became an informant in exchange for leniency. He pleaded guilty to two counts of criminal fraud and was sentenced to a five-year term of probation. [5] A documentary film titled The Blech Effect was released in 2020 documenting his rise and fall in the industry.

Personal

Blech says he is bipolar, has a gambling addiction and is a member of Gamblers Anonymous. [7] [8]

Related Research Articles

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Icos Corporation was an American biotechnology company and the largest biotechnology company in the U.S. state of Washington, before it was sold to Eli Lilly and Company in 2007. It was founded in 1989 by David Blech, Isaac Blech, Robert Nowinski, and George Rathmann, a pioneer in the industry and chief executive officer (CEO) and co-founder of Amgen. Icos focused on the development of drugs to treat inflammatory disorders. During its 17-year history, the company conducted clinical trials of twelve drugs, three of which reached the last phase of clinical trials. Icos also manufactured antibodies for other biotechnology companies.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

<span class="mw-page-title-main">Bio-1</span>

Bio-1 is a consortium of partners founded in 2007 designed to identify and promote bioscience in the Central New Jersey area. It is the result of a $5 million grant made available by the Workforce Innovation in Regional Economic Development (WIRED) program.

<span class="mw-page-title-main">Ivor Royston</span> Researcher

Ivor Royston, M.D., is an oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.

Kosan Biosciences, Inc., was a pharmaceutical company which dealt with cancer therapeutics medications. The company was working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.

<span class="mw-page-title-main">Acceleron Pharma</span> American healthcare company

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

<span class="mw-page-title-main">Juno Therapeutics</span> American biopharmaceutical company

Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Cancer Breakthroughs 2020</span>

Cancer Breakthroughs 2020, also known as Cancer Moonshot 2020 is a coalition with the goal of finding vaccine-based immunotherapies against cancer. By pooling the resources of multinational pharmaceutical, biotechnology companies, academic centers and oncologists, it intends to create access to over 60 novel and approved agents under exploration in the war against cancer and is expected to enable rapid testing of novel immunotherapy combination protocols. The initiative is being managed by a consortium of companies called The National Immunotherapy Coalition.

<span class="mw-page-title-main">Editas Medicine</span> Discovery-phase pharmaceutical company

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Arrakis Therapeutics is a Waltham, Massachusetts-based biopharmaceutical company developing drugs for neurological disorders and other diseases. The company was co-founded in 2015 by Jennifer Petter, PhD, now Chief Innovation Officer Raj Parakh, Alan Walts and Henri Termeer. Arrakis has been led since October 2016 by CEO Michael Gilman, PhD, a former Biogen executive who co-founded and led Padlock Therapeutics and Stromedix.

<span class="mw-page-title-main">Biotechnology industry in Boston</span>

Greater Boston, primarily Boston and Cambridge, is home to more than 1,000 biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies. The many universities in the area give the region a large network of scientists.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders.

<i>The Blech Effect</i> 2020 American documentary film

The Blech Effect is a 2020 documentary film directed by David Greenwald, following former "King of Biotech" David Blech. In his early 20s, Blech was a pioneer investor in biotech companies such as Celgene, Alexion Pharmaceuticals, cancer drug developer Ariad Pharmaceuticals, and Icos, which developed the impotence drug Cialis. Blech's wealth grew with the industry and he was once worth more than 300 million dollars, securing his place on the Forbes 400 list. He became known as the King of Biotech and his influence on the market coined the term “The Blech Effect".

Christopher Henney is a British-American biotechnology company executive and board member. In 1980, he co-founded Immunex Corp., which was later acquired by Amgen Inc.

References

  1. ↑ Williams, Duff. "He helped create the biotech boom and when it went bust, so did he". The Seattle Times.
  2. ↑ Bylinsky, Gene (June 19, 1989). "WHAT A WAY TO START A COMPANY! A pharmaceuticals giant has put more than $70 million into Nova, a fledgling outfit that didn't even have a lab before it went public – and still hasn't marketed a product". CNN.
  3. ↑ "Life Sciences Foundation". July 26, 2016.
  4. ↑ Walters, Donna (February 4, 1986). "Bristol-Myers Agrees to Buy Genetic Systems : Syntex Bought Out of Deal With Biotech Firm". Los Angeles Times. Retrieved February 18, 2012.
  5. 1 2 3 Duff Wilson; David Heath. "He helped create the biotech boom and when it went bust so did he". Uninformed Consent. Retrieved February 18, 2012.
  6. ↑ William P. Barrett; Janet Novack; Daniel Fisher; Matthew Rand. "And Starting to Bark". Forbes. Retrieved February 18, 2012.
  7. ↑ Pollack, Andrew (September 5, 2013). "A Biotech King, Dethroned". The New York Times.
  8. ↑ "David Blech Gets Four Years for Manipulating Stock Prices". Bloomberg.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.